Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. (DNA) from its SEC filings: 2025 revenue $170.2 million (-25% vs the year before), net margin -0%, free cash flow -$178.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $170.2 million |
| Revenue growth | -25% |
| Net income | -$313,000 |
| Net margin | -0.2% |
| Free cash flow | -$178.7 million |
| Diluted EPS | $-5.64 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -48% |
| Cash | $84.5 million |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.